Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers
暂无分享,去创建一个
D. Kuypers | H. de Jonge | H. de Loor | P. Annaert | J. D. de Hoon | T. Vanhove | A. Pohanka | Marlies Oorts | J. de Hoon | Hylke de Jonge
[1] T. Bouillon,et al. Fexofenadine, a Putative In Vivo P‐glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients , 2017, Clinical pharmacology and therapeutics.
[2] D. Lambrechts,et al. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype , 2016, The Pharmacogenomics Journal.
[3] Lydia M. M. Vermeer,et al. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters , 2016, Drug Metabolism and Disposition.
[4] D. Kuypers,et al. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review , 2016, Drug metabolism reviews.
[5] D. Kuypers,et al. Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism. , 2013, Pharmacogenomics.
[6] M. Hebert,et al. Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition , 2012, Clinical pharmacology and therapeutics.
[7] K. Verbeke,et al. In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients , 2012, Clinical pharmacology and therapeutics.
[8] Russ B Altman,et al. PharmGKB summary: very important pharmacogene information for CYP3A5. , 2012, Pharmacogenetics and genomics.
[9] K. Verbeke,et al. A highly sensitive liquid chromatography tandem mass spectrometry method for simultaneous quantification of midazolam, 1'-hydroxymidazolam and 4-hydroxymidazolam in human plasma. , 2011, Biomedical chromatography : BMC.
[10] E. Kharasch,et al. Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam , 2007, Clinical pharmacology and therapeutics.
[11] G. Cook,et al. The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation , 2006, Annals of clinical biochemistry.
[12] Mark Daly,et al. Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..
[13] E. Wang,et al. Interaction of Common Azole Antifungals with P Glycoprotein , 2002, Antimicrobial Agents and Chemotherapy.
[14] P. Donnelly,et al. A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.
[15] N. Undre,et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[16] U. Christians,et al. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. , 1996, Clinical chemistry.
[17] Paul E. Teschan,et al. Glomerular filtration rate measurements in clinical trials , 1993 .
[18] U. Christians,et al. Additive and synergistic effects of cyclosporine metabolites on glomerular mesangial cells. , 1991, Kidney international.
[19] J. Thliveris,et al. Toxicity of Cyclosporine Metabolites , 1990, Therapeutic drug monitoring.
[20] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[21] S. Uemoto,et al. Required transient dose escalation of tacrolimus in living-donor liver transplant recipients with high concentrations of a minor metabolite M-II in bile. , 2008, Drug metabolism and pharmacokinetics.
[22] K. Iwasaki,et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[23] G. Striker. Modification of diet in renal disease. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.